{"model": "mistralai/Mistral-7B-Instruct-v0.1", "do_sample": false, "temperature": 0, "top_p": 1, "top_k": 1, "repetition_penalty": 1, "max_tokens": 2048, "choices": [{"role": "assistant", "text": "## Omissions\n- Original Fragment: \"A1C at week 24 was lower in the etanercept group (5.91 \u00b1 0.5%) compared with that in the placebo group (6.98 \u00b1 1.2%; P < 0.05) with a higher percent decrease from baseline than in the placebo group (etanercept 0.41 \u00b1 0.1 vs. placebo 0.18 \u00b1 0.21; P < 0.01)\"\n- Simplification Fragment: null\n- Rationale: the simplification does not mention the specific values of A1C at week 24 for each group.\n- Question: What was the average A1C level at week 24 for the etanercept group and the placebo group?\n- Answer: The average A1C level at week 24 for the etanercept group was 5.91 \u00b1 0.5% and for the placebo group was 6.98 \u00b1 1.2%.\n\n- Original Fragment: \"The percent change in C-peptide area under the curve from baseline to week 24 showed a 39% increase in the etanercept group and a 20% decrease in the placebo group (P < 0.05)\"\n- Simplification Fragment: null\n- Rationale: the simplification does not mention the specific percent change in C-peptide area under the curve from baseline to week 24 for each group.\n- Question: What was the percent change in C-peptide area under the curve from baseline to week 24 for the etanercept group and the placebo group?\n- Answer: The percent change in C-peptide area under the curve from baseline to week 24 for the etanercept group was 39% and for the placebo group was 20%.\n\n- Original Fragment: \"From baseline to week 24 insulin dose decreased 18% in the etanercept group compared with a 23% increase in the placebo group (P < 0.05)\"\n- Simplification Fragment: null\n- Rationale: the simplification does not mention the specific percent change in insulin dose from baseline to week 24 for each group.\n- Question: What was the percent change in insulin dose from baseline to week 24 for the etanercept group and the placebo group?\n- Answer: The percent change in insulin dose from baseline to week 24 for the etanercept group was 18% and for the placebo group was 23%.\n\n## Imprecise/fuzzy concepts\n- Original Fragment: \"The percent change in C-peptide area under the curve from baseline to week 24 showed a 39% increase in the etanercept group and a 20% decrease in the placebo group (P < 0.05)\"\n- Simplification Fragment: \"The percent change in C-peptide area under the curve from baseline to week 24 was higher in the etanercept group and lower in the placebo group\"\n- Rationale: the simplification does not mention the specific values of the percent change in C-peptide area under the curve from baseline to week 24 for each group.\n- Question: What was the specific value of the percent change in C-peptide area under the curve from baseline to week 24 for the etanercept group and the placebo group?\n- Answer: The specific value of the percent change in C-peptide area under the curve from baseline to week 24 for the etanercept group was 39% and for the placebo group was 20%.\n\n- Original Fragment: \"The percent change in C-peptide area under the curve from baseline to week 24 showed a 39% increase in the etanercept group and a 20% decrease in the placebo group (P < 0.05)\"\n- Simplification Fragment: \"The percent change in C-peptide area under the curve from baseline to week 24 was higher in the etanercept group and lower in the placebo group\"\n- Rationale: the simplification does not mention the statistical significance of the difference in percent change in C-peptide area under the curve from baseline to week 24 between the etanercept group and the placebo group.\n- Question: What was the statistical significance of the difference in percent change in C-peptide area under the curve from baseline to week 24 between the etanercept group and the placebo group?\n- Answer: The statistical significance of the difference in percent change in C-peptide area under the curve from baseline to week 24 between the etanercept group and the placebo group was P < 0.05.", "finish_reason": "stop"}], "messages": [{"role": "user", "content": "You are an expert annotator for outputs of text simplification systems. This annotation task is to identify pieces of information that were lost in the simplification process. You will be given two texts: the original and a simplification. Assume that a lay reader only sees the simplification. Identify all things which the reader can NOT learn from the simplification but that they could have learnt from the original.\n\nPlease classify each unit of information into one of the following two categories:\n\n1. Omissions: Pieces of information which were not included in the simplification.\n2. Imprecise/fuzzy concepts: Pieces of information which are included in the simplification, but that have been simplified to the extent that they became imprecise or completely lost their original meaning.\n\nAfterwards, please write a question-answer pair that would elicit the missing information from the original text. Phrase the question in such a way that a reader can understand it without having seen the original text. It should only contain concepts (entities, events, or states) that were mentioned in the simple text, or concepts that have not been directly mentioned but are generally known or inferable from mentioned ones. The answer should be understandable by an average adult, so please explain technical jargon if necessary. Make each question-answer pair as specific as possible. Ask only about one information unit at a time.\n\nA useful heuristic to decide between omissions and imprecise/fuzzy concepts is to see if the question-answer pair clarifies/expands some topic which is discussed in the simplification. If so, classify it as imprecise/fuzzy concepts, otherwise omission.\n\nAdhere to this output format:\n- Original Fragment: <exact span in original>\n- Simplification Fragment: null for Omissions OR <exact span in simplification> for Imprecise/fuzzy concepts\n- Rationale: <a short rationale that describes what makes this an information loss>\n- Question: <the question that elicits missing information>\n- Answer: <the answer that provides the missing information from the original span>\n\nStrictly include the above elements. There can be many omissions and imprecise concepts, so be exhaustive. Use simple language in the answer. Cite the original/simplification span EXACTLY so that span == text[text.index(span):text.index(span)+len(span)].\n\n## Original\nThis study evaluates the effects of vitamin D3 on disease activity and quality of life in ulcerative colitis (UC) patients with hypovitaminosis D. The study was a prospective double-blinded, randomized trial conducted at Community Regional Medical Center, Fresno, CA from 2012\u20132013. Patients with UC and a serum 25(OH)D level <30 ng/ml were eligible for the study. Enrolled subjects were randomized to receive either 2,000 lU or 4,000 IU of oral vitamin D3 daily for a total of 90 days. The Short IBD Questionnaire (SIBDQ) for quality of life, the Partial Mayo Score for UC disease activity and serum lab tests were compared between the two treatment groups.\n\n## Simplification\nThis study looks at whether taking vitamin D3 can affect a particular form of bowel disease (ulcerative colitis) and improve the lives of patients with low levels of vitamin D. The study was carried out at a medical center in Fresno, California, between 2012 and 2013. Patients with this disease and low vitamin D levels were included. Participants were randomly given either 2,000 IU or 4,000 IU of oral vitamin D3 daily for 90 days. Researchers used a survey about participant's quality of life and conducted lab tests between the two groups."}, {"role": "assistant", "content": "## Omissions\n- Original Fragment: \"Partial Mayo Score for UC disease activity\"\n- Simplification Fragment: null\n- Rationale: the simplification does not mention that the Partial Mayo Score was used.\n- Question: Besides quality of life survey and the serum tests, what other measures did the researchers use?\n- Answer: The researchers also tracked the partial mayo for UC diseases. UC stands for ulcerative colitis and is an inflammatory bowel disease. The mayo score indicates how active or severe the disease is.\n\n## Imprecise/fuzzy concepts\n- Original Fragment: \"The study was a prospective double-blinded, randomized trial\"\n- Simplification Fragment: \"The study\"\n- Rationale: The simplification does not explain the design of the study, it only mentions that it was a \"study\".\n- Question: How did the study control for bias?\n- Answer: The study was double-blinded, so that neither the researcher nor the participants knew which treatment each participant received, and it was randomized, meaning the participants were randomly assigned one of the treatments.\n\n- Original Fragment: \"a serum 25(OH)D level <30 ng/ml\"\n- Simplification Fragment: \"low vitamin D levels\"\n- Rationale: the simplification does not explain the inclusion criteria, namely how low the vitamin D levels of eligible patients were.\n- Question: How low were the vitamin D levels in patients that were included in the study?\n- Answer: Participants in the study all had less than 30ng/ml of vitamin D, which is below the minimum recommendation of vitamin D levels in the body.\n\n- Original Fragment: \"Short IBD Questionnaire (SIBDQ) for quality of life\"\n- Simplification Fragment: \"a survey about participant's quality of life\"\n- Rationale: the specific type of survey (SIBDQ) is not mentioned in the simplification\n- Question: What survey was used to measure participants' quality of life?\n- Answer: The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) was used which gives insights about the physical, social, and emotional status of patients with bowel diseases."}, {"role": "user", "content": "## Original\nOBJECTIVE.\nTo gather preliminary data on the feasibility and efficacy of etanercept therapy to prolong endogenous insulin production in pediatric patients with newly diagnosed type 1 diabetes.\n\nRESEARCH DESIGN AND METHODS.\nThis was a 24-week double-blind, randomized, placebo-controlled study conducted at the Diabetes Center, Women and Children's Hospital of Buffalo. Eighteen subjects (11 male and 7 female, aged 7.8\u201318.2 years) were randomly assigned to receive either placebo or etanercept. Inclusion criteria included age 3\u201318 years, GAD-65 and/or islet cell antibody positivity, A1C >6%, three insulin injections per day, white blood cell count 3,000\u201310,000, platelets >100,000, and normal liver and renal function. Intention-to-treat analysis was used.\n\nRESULTS.\nA1C at week 24 was lower in the etanercept group (5.91 \u00b1 0.5%) compared with that in the placebo group (6.98 \u00b1 1.2%; P < 0.05) with a higher percent decrease from baseline than in the placebo group (etanercept 0.41 \u00b1 0.1 vs. placebo 0.18 \u00b1 0.21; P < 0.01). The percent change in C-peptide area under the curve from baseline to week 24 showed a 39% increase in the etanercept group and a 20% decrease in the placebo group (P < 0.05). From baseline to week 24 insulin dose decreased 18% in the etanercept group compared with a 23% increase in the placebo group (P < 0.05). Seventeen patients completed the study, and none withdrew because of adverse events.\n\nCONCLUSIONS.\nIn this small pilot study, treatment of pediatric patients newly diagnosed with type 1 diabetes with etanercept resulted in lower A1C and increased endogenous insulin production, suggesting preservation of \u03b2-cell function. A larger study is needed to further explore safety and efficacy.\n\n## Simplification\nGOAL.\nThe goal of this study was to test if a drug called etanercept could help children with newly detected type 1 diabetes continue making their own insulin for longer.\n\nSTUDY DESIGN. \nThis was a six-month experiment carried out at the Children's Hospital of Buffalo's Diabetes Center. A diverse group of 18 kids aged between 7.8-18.2 years participated. They were randomly split into two groups. One group received etanercept, and the other got a placebo (a substance with no therapeutic effect). The researchers used standard criteria, including age, health status, insulin injections, and general health markers to select the participants. They treated all participants equally whether they finished the study or not.\n\nFINDINGS. \nAt the end of the study, the group that received etanercept had a lower average blood sugar level and seemed to be making more of their own insulin than the placebo group. Their average insulin dose decreased by 18%, while the placebo group's average dose increased by 23%. Importantly, none of the patients dropped out due to side effects from the etanercept.\n\nCONCLUSIONS. \nThis small preliminary study suggests that etanercept might help children newly diagnosed with type 1 diabetes maintain their ability to produce insulin. Therefore, etanercept might delay the point at which patients need to rely entirely on insulin injections. More extensive research is needed to confirm this possibility and to ensure the safety and effectiveness of this treatment approach."}], "usage": {"prompt_tokens": 2278, "completion_tokens": 1103, "total_tokens": 3381}}